NFKB1 and B-cell non-Hodgkin lymphoma: The possibility that NF-κB subunits have distinct roles also in the biology of a malignancy should be taken into consideration when determining the oncogenic effects of aberrant NF-κB activation in B-cell lymphomas, as this knowledge may be exploited for the development of more specific drugs with reduced systemic toxicity.